RNS Number : 6273L
N4 Pharma PLC
14 September 2021

14 September 2021

N4 Pharma plc
("**N4 Pharma**" or the "**Company**")

Operations Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its current *in vivo* work streams due to commence shortly with Evotec.

As announced on 24 August 2021, the Company has now successfully completed the amplification and initial testing of a new SARS-COV-2 plasmid at Evotec and finalised the scope of the *in vivo* study. The first step in this new study was to test the *in vitro* performance of the new plasmid. The optimised Nuvec®, together with the new SARS-COV-2 plasmid has demonstrated an improved response in terms of transfection and SARS-COV-2 Spike protein secretion in HEK 293 cells, a commonly used human cell line. In addition, the Nuvec®/SARS-COV-2 DNA complex demonstrated a dose-related SARS-COV-2 Spike protein production. These *in vitro* results provide a positive platform for the commencement of the *in vivo* work beginning this month which is expected to last six to eight weeks with an additional two to three weeks for analysis.

Nanomerics's wider *in vivo* study, as announced on 20 May 2021, has now validated the results seen from their earlier pilot study, showing an improvement through the use of newly formulated and dried Nuvec®. The findings of this work will now be adopted in all future work undertaken to ensure all studies are performed using well dispersed Nuvec® formulations.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"The Board is very pleased with these initial *in vitro* results from the new SARS-COV-2 plasmid which confirms Nuvec® is capable of producing results in this area and demonstrate a material improvement on previous results with an earlier plasmid.

"We are very excited to commence the *in vivo* work using this SARS-COV-2 plasmid alongside the MTA (Material Transfer Agreement) work already in place with a potential partner in this area. The aim of the study is to

demonstrate the potential of using Nuvec® to develop plasmid DNA vaccines using much lower doses than those already approved or are in development and also not requiring refrigeration."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.

Enquiries:

N4 Pharma plc

Nigel Theobald, CEO — Via IFC Advisory

Luke Cairns, Executive Director

SP Angel Corporate Finance LLP — Tel: +44(0)20 3470 0470

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited — Tel: +44(0)20 3657 0050

Joint Broker

Andy Thacker

IFC Advisory Ltd — Tel: +44(0)20 3934 6630

Financial PR

Graham Herring

Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDLJMRTMTMBBPB